Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 107.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 205,943 shares of the company’s stock after purchasing an additional 106,823 shares during the period. JPMorgan Chase & Co. owned about 0.16% of Organogenesis worth $589,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Captrust Financial Advisors acquired a new stake in Organogenesis in the third quarter valued at approximately $36,000. Intech Investment Management LLC acquired a new stake in shares of Organogenesis in the third quarter worth approximately $43,000. Pallas Capital Advisors LLC boosted its stake in shares of Organogenesis by 70.8% in the third quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after acquiring an additional 9,048 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of Organogenesis by 46.1% in the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after acquiring an additional 7,678 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Organogenesis in the third quarter worth approximately $72,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Organogenesis

In related news, CEO Gary S. Gillheeney sold 41,052 shares of Organogenesis stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $3.52, for a total transaction of $144,503.04. Following the transaction, the chief executive officer now owns 3,359,726 shares in the company, valued at approximately $11,826,235.52. This trade represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 278,116 shares of company stock valued at $991,190 over the last ninety days. Insiders own 36.90% of the company’s stock.

Organogenesis Stock Performance

Shares of NASDAQ:ORGO opened at $3.74 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The business’s 50 day moving average price is $3.47 and its 200-day moving average price is $3.12. The firm has a market capitalization of $470.23 million, a PE ratio of -62.33 and a beta of 1.77. Organogenesis Holdings Inc. has a 1 year low of $2.16 and a 1 year high of $4.57.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The firm had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the previous year, the company posted $0.02 earnings per share. As a group, equities research analysts expect that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.